Cost-effectiveness analysis of addiction treatment: paradoxes of multiple outcomes

被引:85
|
作者
Sindelar, JL
Jofre-Bonet, M
French, MT
McLellan, AT
机构
[1] Yale Univ, Sch Publ Hlth, New Haven, CT 06520 USA
[2] Yale Univ, Sch Med, New Haven, CT 06520 USA
[3] Natl Bur Econ Res, Cambridge, MA 02138 USA
[4] London Sch Hyg & Trop Med, London WC2A 2AE, England
[5] Univ London London Sch Econ & Polit Sci, Dept Econ, London WC2A 2AE, England
[6] Univ Miami, Dept Sociol, Coral Gables, FL 33124 USA
[7] Univ Penn, Treatment Res Inst, Dept Psychiat, Philadelphia, PA 19106 USA
关键词
cost-effectiveness analysis; treatment; services; economics;
D O I
10.1016/j.drugalcdep.2003.09.002
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
This paper identifies and illustrates the challenges of conducting cost-effectiveness analysis (CEA) of addiction treatments given the multiple important outcomes of substance abuse treatment (SAT). Potential problems arise because CEA is intended primarily for single outcome programs, yet addiction treatment results in a variety of outcomes such as reduced drug use and crime and increased employment. Methodological principles, empirical examples, and practical advice are offered on how to conduct an economic evaluation given multiple outcomes. An empirical example is provided to illustrate some of the conflicts in cost-effectiveness (CE) ratios that may arise across the range of outcomes. The data are from the Philadelphia Target Cities quasi-experimental field study of standard versus "enhanced" (e.g. case management and added social services) drug treatment. Outcomes are derived from of the Addiction Severity Index (ASI), while cost data were collected and analyzed using the Drug Abuse Treatment Cost Analysis Program (DATCAP). While the results are illustrative only, they indicate that cost-effectiveness ratios for each of several different outcomes can produce conflicting implications. These findings suggest that multiple outcomes should be considered in any economic analysis of addiction treatments because focusing on a single outcome may lead to inadequate and possibly incorrect policy inferences. However, incorporating multiple outcomes into a CEA of addiction treatment is difficult. Cost-benefit analysis (CBA) may be a preferable and more appropriate approach in some cases. (C) 2003 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:41 / 50
页数:10
相关论文
共 50 条
  • [41] Cost-effectiveness analysis of ponatinib in the treatment of CML in Germany
    Le Coutre, P.
    Hirt, C.
    Lannazzo, S.
    Brenn, J.
    Chiroli, S.
    Oncology Research and Treatment, 2015, 38 : 131 - 132
  • [42] A Cost-Effectiveness Analysis of Pegcetacoplan for the Treatment of Geographic Atrophy
    Patel, Nimesh A.
    Al-Khersan, Hasenin
    Yannuzzi, Nicolas A.
    Lin, James
    Smiddy, William E.
    OPHTHALMOLOGY, 2024, 131 (02) : 129 - 129
  • [43] COST-EFFECTIVENESS ANALYSIS OF GOLIMUMAB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
    Desai, R. J.
    Rao, J.
    Biddle, A. K.
    VALUE IN HEALTH, 2012, 15 (04) : A39 - A39
  • [44] COST-EFFECTIVENESS ANALYSIS OF ANIDULAFUNGIN IN THE TREATMENT OF CANDIDEMIA IN CHILE
    Gutierrez-Ardila, M., V
    Kriguer Hitelman, D.
    Solar Tobar, F.
    VALUE IN HEALTH, 2015, 18 (03) : A239 - A239
  • [45] Cost-Effectiveness Analysis of Cardiovascular Disease Treatment in Japan
    Kodera, Satoshi
    Kiyosue, Arihiro
    Ando, Jiro
    Akazawa, Hiroshi
    Morita, Hiroyuki
    Watanabe, Masafumi
    Komuro, Issei
    INTERNATIONAL HEART JOURNAL, 2017, 58 (06) : 847 - 852
  • [46] Bayesian cost-effectiveness analysis of treatment of ankylosing spondylitis
    Jansen, J. P.
    Gaugris, S.
    Stam, W.
    VALUE IN HEALTH, 2008, 11 (03) : A263 - A263
  • [47] Treatment for early endometrial cancer - Cost-effectiveness analysis
    Fanning, J
    JOURNAL OF REPRODUCTIVE MEDICINE, 1999, 44 (08) : 719 - 723
  • [48] A Cost-effectiveness Analysis of Antipsychotics for Treatment of Schizophrenia in Uganda
    Solomon J. Lubinga
    Byamah B. Mutamba
    Angelo Nganizi
    Joseph B. Babigumira
    Applied Health Economics and Health Policy, 2015, 13 : 493 - 506
  • [49] Treatment of migraine in Canada with naratriptan: A cost-effectiveness analysis
    Caro, JJ
    Getsios, D
    Raggio, G
    Caro, G
    Black, L
    HEADACHE, 2001, 41 (05): : 456 - 464
  • [50] COST-EFFECTIVENESS ANALYSIS FOR TREATMENT OF VISCERAL LEISHMANIASIS IN ARMENIA
    Apresyan, Hripsime
    Grigoryan, Erik
    Grigoryan, Mark
    Tsarukyan, Edgar
    Asoyan, Vigen
    ARCHIVES OF DISEASE IN CHILDHOOD, 2019, 104 : A299 - A300